Johnson, Leonard B.
Ramani, Ananthakrishnan
Guervil, David J.
Funding for this research was provided by:
Allergan plc
Article History
Received: 1 October 2018
Accepted: 7 February 2019
First Online: 21 February 2019
Ethics approval and consent to participate
: This study was submitted to and approved by appropriate institutional review boards (IRBs) as listed in Additional file InternalRef removed: Table S1. This study was conducted in compliance with the International Conference on Harmonisation (ICH) Technical Requirements for Registration of Pharmaceuticals for Human Use: Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance (1996), Good Pharmacoepidemiology Practice, Health Insurance Portability and Accountability Act, 21 CFR Part 11, and any additional national or IRB requirements. Due to the retrospective nature of data collection for this study, patient written consent was waived or collected before data extraction as appropriate based on individual site IRB requirements <b>(</b>Additional file InternalRef removed: Table S1<b>)</b>.
: Not applicable; individual patient data are not presented.
: Financial arrangements of the authors with companies whose products may be related to the present report are listed below, as declared by the authors. LBJ has received research support from Allergan. AR has served as a speaker for Allergan and Gilead. DJG has received clinical research support from Durata Therapeutics Inc. (now Allergan plc).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.